Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 37 | 2023 | 501 | 7.520 |
Why?
|
| Neoplasms | 17 | 2021 | 1341 | 2.920 |
Why?
|
| Gene Expression Regulation, Neoplastic | 24 | 2021 | 933 | 2.260 |
Why?
|
| Exosomes | 9 | 2020 | 124 | 1.950 |
Why?
|
| RNA, Neoplasm | 4 | 2021 | 25 | 1.690 |
Why?
|
| Killer Cells, Natural | 3 | 2021 | 99 | 1.320 |
Why?
|
| Lung Neoplasms | 6 | 2021 | 479 | 1.290 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 290 | 1.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 130 | 1.180 |
Why?
|
| Neuroblastoma | 3 | 2021 | 134 | 1.140 |
Why?
|
| Immunotherapy | 4 | 2021 | 137 | 1.130 |
Why?
|
| Cell Communication | 5 | 2021 | 110 | 1.000 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2018 | 61 | 0.780 |
Why?
|
| Toll-Like Receptors | 2 | 2013 | 51 | 0.780 |
Why?
|
| RNA | 2 | 2023 | 266 | 0.760 |
Why?
|
| RNA, Untranslated | 2 | 2019 | 46 | 0.740 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2021 | 21 | 0.730 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 55 | 0.710 |
Why?
|
| Humans | 52 | 2023 | 42163 | 0.680 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 159 | 0.670 |
Why?
|
| Conserved Sequence | 2 | 2017 | 121 | 0.660 |
Why?
|
| Oncogenes | 2 | 2018 | 44 | 0.650 |
Why?
|
| Dendritic Cells | 3 | 2017 | 130 | 0.650 |
Why?
|
| Animals | 28 | 2021 | 16695 | 0.610 |
Why?
|
| Mutation | 2 | 2021 | 1169 | 0.520 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2021 | 339 | 0.500 |
Why?
|
| Cell Proliferation | 9 | 2018 | 1420 | 0.450 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 228 | 0.450 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 26 | 0.430 |
Why?
|
| Signal Transduction | 5 | 2017 | 2111 | 0.400 |
Why?
|
| Mice | 16 | 2021 | 6490 | 0.400 |
Why?
|
| Melanoma | 1 | 2014 | 109 | 0.390 |
Why?
|
| Monocytes | 1 | 2015 | 275 | 0.390 |
Why?
|
| Cell Line, Tumor | 14 | 2021 | 2598 | 0.390 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 175 | 0.380 |
Why?
|
| Epigenesis, Genetic | 2 | 2018 | 274 | 0.380 |
Why?
|
| Mice, Inbred NOD | 3 | 2021 | 50 | 0.360 |
Why?
|
| Mice, SCID | 3 | 2021 | 158 | 0.350 |
Why?
|
| Inflammation | 2 | 2017 | 729 | 0.290 |
Why?
|
| Tumor Escape | 2 | 2019 | 14 | 0.290 |
Why?
|
| Cisplatin | 3 | 2018 | 91 | 0.280 |
Why?
|
| Stromal Cells | 2 | 2016 | 54 | 0.240 |
Why?
|
| Female | 17 | 2023 | 24018 | 0.230 |
Why?
|
| Mice, Nude | 6 | 2017 | 403 | 0.220 |
Why?
|
| Immunity, Innate | 2 | 2016 | 168 | 0.220 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2022 | 40 | 0.210 |
Why?
|
| Apoptosis | 6 | 2018 | 1541 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 181 | 0.200 |
Why?
|
| Toll-Like Receptor 8 | 3 | 2022 | 5 | 0.200 |
Why?
|
| Transplantation, Homologous | 2 | 2019 | 37 | 0.190 |
Why?
|
| Adenocarcinoma | 3 | 2015 | 287 | 0.180 |
Why?
|
| RNA, Messenger | 4 | 2020 | 1265 | 0.180 |
Why?
|
| Ligands | 2 | 2013 | 387 | 0.180 |
Why?
|
| Disease Progression | 3 | 2021 | 661 | 0.180 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 29 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2021 | 50 | 0.170 |
Why?
|
| Down-Regulation | 4 | 2017 | 452 | 0.170 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 37 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 284 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 249 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 506 | 0.170 |
Why?
|
| Male | 11 | 2021 | 22779 | 0.170 |
Why?
|
| Cell Differentiation | 2 | 2014 | 633 | 0.160 |
Why?
|
| Base Sequence | 3 | 2017 | 997 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 81 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 979 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2020 | 317 | 0.150 |
Why?
|
| Leukemia | 2 | 2010 | 54 | 0.150 |
Why?
|
| Nucleic Acid Conformation | 1 | 2019 | 156 | 0.150 |
Why?
|
| NF-kappa B | 3 | 2017 | 355 | 0.140 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2018 | 1 | 0.140 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2018 | 97 | 0.140 |
Why?
|
| Up-Regulation | 2 | 2017 | 534 | 0.140 |
Why?
|
| Prognosis | 5 | 2017 | 850 | 0.140 |
Why?
|
| Cyclins | 1 | 2017 | 37 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 51 | 0.140 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2017 | 18 | 0.140 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 502 | 0.140 |
Why?
|
| Gene Expression Profiling | 3 | 2010 | 683 | 0.140 |
Why?
|
| Drug Resistance | 1 | 2018 | 97 | 0.130 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2017 | 1 | 0.130 |
Why?
|
| Keratinocytes | 1 | 2017 | 67 | 0.130 |
Why?
|
| Graft vs Host Disease | 1 | 2017 | 15 | 0.130 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 1679 | 0.130 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 81 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 53 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2019 | 1586 | 0.130 |
Why?
|
| Lung | 2 | 2017 | 484 | 0.130 |
Why?
|
| RNA Transport | 1 | 2016 | 1 | 0.130 |
Why?
|
| Proteins | 1 | 2019 | 383 | 0.130 |
Why?
|
| Viruses | 1 | 2016 | 39 | 0.120 |
Why?
|
| DNA | 1 | 2019 | 594 | 0.120 |
Why?
|
| Biological Transport | 1 | 2016 | 201 | 0.120 |
Why?
|
| Oxidoreductases | 2 | 2007 | 79 | 0.120 |
Why?
|
| Immune System | 1 | 2016 | 40 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2023 | 649 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2016 | 124 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 363 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 206 | 0.120 |
Why?
|
| Cell Lineage | 2 | 2014 | 104 | 0.120 |
Why?
|
| Models, Molecular | 1 | 2019 | 875 | 0.120 |
Why?
|
| Sepsis | 1 | 2016 | 90 | 0.120 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 3 | 0.120 |
Why?
|
| Receptor Cross-Talk | 1 | 2015 | 18 | 0.120 |
Why?
|
| Transcription, Genetic | 3 | 2015 | 599 | 0.120 |
Why?
|
| Paracrine Communication | 1 | 2015 | 18 | 0.120 |
Why?
|
| Telomere-Binding Proteins | 1 | 2015 | 11 | 0.120 |
Why?
|
| Galectin 3 | 1 | 2015 | 29 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 137 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 84 | 0.110 |
Why?
|
| Coculture Techniques | 1 | 2015 | 105 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 165 | 0.110 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2015 | 8 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 32 | 0.110 |
Why?
|
| Transfection | 5 | 2015 | 526 | 0.100 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2013 | 4 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2018 | 406 | 0.100 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2013 | 27 | 0.100 |
Why?
|
| Macrophages | 1 | 2016 | 515 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 223 | 0.090 |
Why?
|
| Carcinoma | 1 | 2011 | 106 | 0.080 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 36 | 0.080 |
Why?
|
| Models, Biological | 1 | 2012 | 711 | 0.080 |
Why?
|
| Protein Binding | 1 | 2012 | 1076 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 301 | 0.080 |
Why?
|
| Endometrial Neoplasms | 1 | 2010 | 79 | 0.070 |
Why?
|
| Cytokines | 1 | 2013 | 661 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 228 | 0.070 |
Why?
|
| Cytogenetics | 1 | 2008 | 3 | 0.070 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2008 | 8 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2007 | 222 | 0.070 |
Why?
|
| Multigene Family | 1 | 2008 | 105 | 0.070 |
Why?
|
| Middle Aged | 7 | 2018 | 11819 | 0.060 |
Why?
|
| Aged | 6 | 2018 | 7982 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 2803 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 1848 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2022 | 35 | 0.050 |
Why?
|
| Estrogen Receptor alpha | 1 | 2023 | 120 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2018 | 393 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 366 | 0.050 |
Why?
|
| Estrogens | 1 | 2023 | 202 | 0.050 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 1068 | 0.050 |
Why?
|
| Estradiol | 1 | 2023 | 269 | 0.040 |
Why?
|
| Cell Growth Processes | 2 | 2014 | 43 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2015 | 1010 | 0.040 |
Why?
|
| Cell Movement | 2 | 2016 | 640 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 1058 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 1804 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 310 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2018 | 11 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 928 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 378 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2018 | 146 | 0.030 |
Why?
|
| Blotting, Northern | 2 | 2009 | 149 | 0.030 |
Why?
|
| RNA Editing | 1 | 2018 | 37 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2010 | 884 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2017 | 69 | 0.030 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2017 | 11 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2017 | 108 | 0.030 |
Why?
|
| Molecular Mimicry | 1 | 2016 | 16 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 156 | 0.030 |
Why?
|
| Adult | 4 | 2018 | 13458 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 165 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2017 | 170 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 658 | 0.030 |
Why?
|
| Austria | 1 | 2015 | 5 | 0.030 |
Why?
|
| Romania | 1 | 2015 | 6 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 27 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2015 | 60 | 0.030 |
Why?
|
| Galectins | 1 | 2015 | 29 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2015 | 75 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 379 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 436 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 173 | 0.030 |
Why?
|
| Endocytosis | 1 | 2015 | 117 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 233 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 438 | 0.030 |
Why?
|
| Poly I-C | 1 | 2013 | 7 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 860 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 602 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 181 | 0.020 |
Why?
|
| Tretinoin | 1 | 2013 | 50 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 1729 | 0.020 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 1 | 2012 | 2 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2012 | 40 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2012 | 32 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 44 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 84 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 144 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 246 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 174 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 75 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 362 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1266 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 1554 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2008 | 12 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2008 | 14 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2008 | 19 | 0.020 |
Why?
|
| Trisomy | 1 | 2008 | 11 | 0.020 |
Why?
|
| Karyotyping | 1 | 2008 | 44 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2008 | 30 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1051 | 0.020 |
Why?
|
| Proteome | 1 | 2008 | 150 | 0.020 |
Why?
|
| Stem Cells | 1 | 2008 | 151 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2006 | 21 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2006 | 62 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 692 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 98 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 129 | 0.020 |
Why?
|
| Cell Line | 1 | 2010 | 1416 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 1617 | 0.020 |
Why?
|
| Proteomics | 1 | 2008 | 363 | 0.010 |
Why?
|
| Adolescent | 1 | 2008 | 5950 | 0.010 |
Why?
|